Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Impaired phagocytic capacity driven by downregulation of major phagocytosis-related cell surface molecules elicits an overall modulatory cytokine profile in neutrophils and monocytes from the indeterminate clinical form of Chagas disease.

Gomes JA, Campi-Azevedo AC, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar D, Sathler-Avelar R, Peruhype-Magalhães V, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, Eloi-Santos S, Martins-Filho OA.

Immunobiology. 2012 Oct;217(10):1005-16. doi: 10.1016/j.imbio.2012.01.014. Epub 2012 Jan 20.

PMID:
22387073
2.
3.

Inflammatory mediators from monocytes down-regulate cellular proliferation and enhance cytokines production in patients with polar clinical forms of Chagas disease.

Gomes JA, Molica AM, Keesen TS, Morato MJ, de Araujo FF, Fares RC, Fiuza JA, Chaves AT, Pinheiro V, Nunes Mdo C, Correa-Oliveira R, da Costa Rocha MO.

Hum Immunol. 2014 Jan;75(1):20-8. doi: 10.1016/j.humimm.2013.09.009. Epub 2013 Sep 24.

PMID:
24071371
4.

Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease.

Vitelli-Avelar DM, Sathler-Avelar R, Teixeira-Carvalho A, Pinto Dias JC, Gontijo ED, Faria AM, Elói-Santos SM, Martins-Filho OA.

Scand J Immunol. 2008 Nov;68(5):516-25. doi: 10.1111/j.1365-3083.2008.02167.x. Epub 2008 Sep 18.

5.

Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory events.

Campi-Azevedo AC, Gomes JA, Teixeira-Carvalho A, Silveira-Lemos D, Vitelli-Avelar DM, Sathler-Avelar R, Peruhype-Magalhães V, Béla SR, Silvestre KF, Batista MA, Schachnik NC, Correa-Oliveira R, Eloi-Santos SM, Martins-Filho OA.

Immunobiology. 2015 May;220(5):564-74. doi: 10.1016/j.imbio.2014.12.006. Epub 2015 Jan 8.

PMID:
25648688
6.

Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity.

Souza PE, Rocha MO, Rocha-Vieira E, Menezes CA, Chaves AC, Gollob KJ, Dutra WO.

Infect Immun. 2004 Sep;72(9):5283-91.

7.

Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens.

Sathler-Avelar R, Vitelli-Avelar DM, Elói-Santos SM, Gontijo ED, Teixeira-Carvalho A, Martins-Filho OA.

BMC Infect Dis. 2012 May 24;12:123. doi: 10.1186/1471-2334-12-123.

8.

Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi.

Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, Silva ED, Ferreira AG, Morais CN, Costa VM, Correa-Oliveira R, Gomes YM.

Scand J Immunol. 2010 Dec;72(6):529-39. doi: 10.1111/j.1365-3083.2010.02462.x.

9.

Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile.

Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, Dias JC, Elói-Santos SM, Martins-Filho OA.

Scand J Immunol. 2006 Nov;64(5):554-63.

10.

Troponin T autoantibodies correlate with chronic cardiomyopathy in human Chagas disease.

Nunes DF, Guedes PM, Andrade Cde M, Câmara AC, Chiari E, Galvão LM.

Trop Med Int Health. 2013 Oct;18(10):1180-92. doi: 10.1111/tmi.12169. Epub 2013 Aug 1.

11.

Foxp3+CD25(high) CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity.

de Araújo FF, Corrêa-Oliveira R, Rocha MO, Chaves AT, Fiuza JA, Fares RC, Ferreira KS, Nunes MC, Keesen TS, Damasio MP, Teixeira-Carvalho A, Gomes JA.

Immunobiology. 2012 Aug;217(8):768-77. doi: 10.1016/j.imbio.2012.04.008. Epub 2012 May 9.

PMID:
22672991
13.

In-house ELISA method to analyze anti-Trypanosoma cruzi IgG reactivity for differential diagnosis and evaluation of Chagas disease morbidity.

Santos Lda S, Torres RM, Machado-de-Assis GF, Bahia MT, Martins HR, Teixeira-Carvalho A, Coelho-Dos-Reis JG, Albajar-Viñas P, Martins-Filho OA, Lana Md.

Rev Soc Bras Med Trop. 2012 Feb;45(1):35-44.

14.
15.

Chagas' disease: IgG isotypes against cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens of Trypanosoma cruzi in chronic Chagasic patients.

Verçosa AF, Lorena VM, Carvalho CL, Melo MF, Cavalcanti MG, Silva ED, Ferreira AG, Pereira VR, Souza WV, Gomes YM.

J Clin Lab Anal. 2007;21(5):271-6.

PMID:
17847109
16.

Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease.

Morgan J, Dias JC, Gontijo ED, Bahia-Oliveira L, Correa-Oliveira R, Colley DG, Powell MR.

Am J Trop Med Hyg. 1996 Oct;55(4):355-9.

PMID:
8916788
17.
18.

Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory.

Vitelli-Avelar DM, Sathler-Avelar R, Wendling AP, Rocha RD, Teixeira-Carvalho A, Martins NE, Dias JC, Rassi A, Luquetti AO, Elói-Santos SM, Martins-Filho OA.

J Immunol Methods. 2007 Jan 10;318(1-2):102-12. Epub 2006 Nov 13.

PMID:
17161421
19.

Cellular immune response from Chagasic patients to CRA or FRA recombinant antigens of Trypanosoma cruzi.

Lorena VM, Verçosa AF, Machado RC, Moitinho-Silva L, Cavalcanti MG, Silva ED, Ferreira AG, Correa-Oliveira R, Pereira VR, Gomes YM.

J Clin Lab Anal. 2008;22(2):91-8. doi: 10.1002/jcla.20209.

PMID:
18348314
20.

Immunological imbalance between IFN-gamma and IL-10 levels in the sera of patients with the cardiac form of Chagas disease.

D'Avila DA, Guedes PM, Castro AM, Gontijo ED, Chiari E, Galvão LM.

Mem Inst Oswaldo Cruz. 2009 Feb;104(1):100-5.

Supplemental Content

Support Center